Product logins

Find logins to all Clarivate products below.


Graft-Versus-Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019

GVHD is a potentially life-threatening complication of allogenic HCST. GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue as foreign. For decades, steroids have been the first-line therapy for the prevention and treatment of GVHD, but interviewed experts call for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for GVHD. Although development in the space has historically been slow, the pipeline for GVHD therapies is now robust with a number of late-phase agents, including Mesoblast’s Prochymal (remestemcel-L), Incyte’s itacitinib, Kadmon’s KD025, Elsalys’s Leukotac (inolimomab), and Takeda’s Entyvio (vedolizumab). Here, we examine the clinical and commercial opportunity for these emerging therapies and how they may affect the commercial performance of current therapies, such as Janssen’s Imbruvica and Incyte / Novartis’s Jakafi / Jakavi (ruxolitinib).

QUESTIONS ANSWERED

  • How large is the GVHD population, and how will it change through 2028? What percentage of the GVHD population receives drug treatment?
  • How is GVHD currently managed in the United States and EU5? How well does the GVHD pipeline align with unmet needs in the space?
  • Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of GVHD? Which emerging drugs hold the most commercial potential?
  • What are some of the key GVHD market drivers and constraints? How will continuing advances in patient and host HLA matching affect the market?

CONTENT HIGHLIGHTS

  • Geographies: United States and EU5
  • Primary Research: Six country-specific interviews with thought-leading GVHD specialists Supported by survey data collected for this study
  • Epidemiology: Diagnosed incident cases of acute and chronic GVHD, diagnosed incident cases of acute GVHD by grade, drug-treated cases of GVHD by country
  • Forecast: Drug-level sales and patient share of key GVHD therapies in 2028
  • Emerging Therapies: Phase III/PR: 6 drugs; Phase II: >10 drugs; coverage of select preclinical and Phase I products

Related Market Assessment Reports

Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…